Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.

Abstract:

:Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of inpatients diagnosed with schizophrenia in 2010 were derived from the reimbursement database of Wuhan and Wuxi. A total of 5251 inpatients received antipsychotic medications, of whom 29.0% received second-generation antipsychotics apart from clozapine (SGAs#), 13.7% received clozapine (CLO), 13.5% received first-generation antipsychotics (FGAs), 43.8% received at least both drug classes, and 5.1% used FGAs, CLO as well as SGAs#. Multinomial logistic regression for 2904 identified inpatients showed that factors of drug reimbursement policy, duration of hospitalization, age group, and municipality were statistically significant in antipsychotic medication. Drug list B and the 25-45 age group presented a significant relationship with SGAs# prescription (FGAs vs. SGAs#). Furthermore, the 12-30-day duration of hospitalization and the 25-45 age group showed a significant relationship with SGAs# prescription (CLO vs. SGAs#). Socioeconomic factors such as health insurance policies, especially reimbursement policy of drugs and payment system, as well as mental health resource distribution are important in antipsychotic prescription in China.

authors

Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

doi

10.1097/YIC.0000000000000024

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

288-95

issue

5

eissn

0268-1315

issn

1473-5857

journal_volume

29

pub_type

杂志文章
  • Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?

    abstract::This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression. This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been dopami...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Miyaoka H,Kamijima K

    更新日期:1995-11-01 00:00:00

  • Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.

    abstract::Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200203000-00005

    authors: Slaap BR,Boshuisen ML,van Roon AM,den Boer JA

    更新日期:2002-03-01 00:00:00

  • Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

    abstract::One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Goodman WK,Kozak MJ,Liebowitz M,White KL

    更新日期:1996-03-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.

    abstract::To compare the efficacy and tolerability of moclobemide versus paroxetine for the treatment of depression with comorbid anxiety disorders. Outpatients fulfilling DSM-III-R criteria for major depression or dysthymia and for a co-occurring comorbid anxiety disorder (panic disorder, generalized anxiety disorder or obsess...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200301000-00003

    authors: Pini S,Amador XF,Dell'Osso L,Baldini Rossi N,Cassano P,Savino M,Cassano GB

    更新日期:2003-01-01 00:00:00

  • Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

    abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283400cd3

    authors: Kim SH,Reaven G,Lindley S

    更新日期:2011-01-01 00:00:00

  • Therapeutic receptor-blocking concentrations of neuroleptics.

    abstract::The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Seeman P

    更新日期:1995-09-01 00:00:00

  • Pharmacotherapy of bulimia nervosa--experience with fluoxetine.

    abstract::A number of compounds having an effect on serotonergic transmission have been shown to have a beneficial therapeutic action in patients with bulimia nervosa. Many previous studies, however, have suffered from methodological shortcomings, in particular small population sizes. This article reviews present data which sug...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-199300840-00014

    authors: Wood A

    更新日期:1993-01-01 00:00:00

  • Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline.

    abstract::A total of 101 patients entered a double-blind, parallel-group study in general practice, comparing the efficacy and tolerability of paroxetine and amitriptyline in elderly depressed patients. All patients received placebo for 1 week followed by active therapy for a total of 6 weeks. Medication was randomly allocated,...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199206004-00009

    authors: Hutchinson DR,Tong S,Moon CA,Vince M,Clarke A

    更新日期:1992-06-01 00:00:00

  • Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

    abstract::The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/00004850-200507000-00002

    authors: Gasquet I,Haro JM,Novick D,Edgell ET,Kennedy L,Lepine JP,SOHO Study Group.

    更新日期:2005-07-01 00:00:00

  • The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.

    abstract::In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Greil W,Kleindienst N

    更新日期:1999-09-01 00:00:00

  • Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.

    abstract::We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/YIC.0000000000000177

    authors: Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

    更新日期:2017-09-01 00:00:00

  • Issues in the design of trials for the evaluation of psychopharmacological treatments for social phobia.

    abstract::Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199606003-00009

    authors: Liebowitz MR,Heimberg RG

    更新日期:1996-06-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • Depression in the community: results of the first Italian survey.

    abstract::The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200101000-00006

    authors: Dubini A,Mannheimer R,Pancheri P

    更新日期:2001-01-01 00:00:00

  • DIABCARE Quality Network in Europe--a model for quality management in chronic diseases.

    abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200104003-00002

    authors: Piwernetz K

    更新日期:2001-04-01 00:00:00

  • Efficacy of risperidone in treating the hyperactive symptoms of delirium.

    abstract::Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200405000-00008

    authors: Liu CY,Juang YY,Liang HY,Lin NC,Yeh EK

    更新日期:2004-05-01 00:00:00

  • Rationalizing antidepressants for elderly people.

    abstract::A rational approach to the use of antidepressants in the elderly must consider the evidence as to whether such treatment is efficacious (in controlled trials) and effective in clinical practice. Effective treatment of depression depends on its detection, and the subsequent initiation and continuation of adequate treat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199503001-00007

    authors: Katona C

    更新日期:1995-03-01 00:00:00

  • Theory and practice in the management of depressive disorders.

    abstract::Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199906003-00004

    authors: Linden M

    更新日期:1999-06-01 00:00:00

  • Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.

    abstract::The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200501000-00003

    authors: Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

    更新日期:2005-01-01 00:00:00

  • Current aspects of valproate in bipolar disorder.

    abstract::For more than 30 years, lithium has been the drug of choice for the treatment of bipolar disorder. However, it has numerous adverse effects, a relatively slow onset of action, many common drug-drug interactions, and a narrow therapeutic index. Because of these problems, researchers looked for alternative and/or adjunc...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200015010-00001

    authors: Lennkh C,Simhandl C

    更新日期:2000-01-01 00:00:00

  • Social adjustment in depressed patients treated with venlafaxine and amitriptyline.

    abstract::Social dysfunction is often associated with depressive disorders and its evaluation is an important measure of treatment outcome. The aim of this study was to assess the effect of two treatments, venlafaxine and amitriptyline, on the social functioning of depressed patients. Twenty-eight outpatients, meeting criteria ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200207000-00003

    authors: Gorenstein C,Andrade L,Moreno RA,Artes R

    更新日期:2002-07-01 00:00:00

  • Carbamazepine compared to haloperidol in acute mania.

    abstract::In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00005

    authors: Brown D,Silverstone T,Cookson J

    更新日期:1989-07-01 00:00:00

  • Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

    abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000097

    authors: Peselow ED,Clevenger S,IsHak WW

    更新日期:2016-07-01 00:00:00

  • Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

    abstract::Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000016

    authors: Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

    更新日期:2014-03-01 00:00:00

  • Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder.

    abstract::Since the discovery that clomipramine was effective in the treatment of obsessive-compulsive disorder (OCD), trials of several different medications for OCD have been published. The question of which agent, if any, is the medication of choice in OCD is of real clinical concern. Published clinical trials were collected...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-199503000-00002

    authors: Stein DJ,Spadaccini E,Hollander E

    更新日期:1995-03-01 00:00:00

  • A novel approach to rater training and certification in multinational trials.

    abstract::Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280803dad

    authors: Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

    更新日期:2007-07-01 00:00:00

  • Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?

    abstract::The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Ashford JJ

    更新日期:1995-01-01 00:00:00

  • A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed.

    abstract::While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patient...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200309000-00006

    authors: Papakostas GI,Petersen T,Worthington JJ,Roffi PA,Alpert JE,Fava M,Nierenberg AA

    更新日期:2003-09-01 00:00:00

  • Effect of moclobemide on the psychophysiology of sleep/wake cycles: a neuroelectrophysiological study of depressed patients administered with moclobemide.

    abstract::The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199300730-00009

    authors: Minot R,Luthringer R,Macher JP

    更新日期:1993-01-01 00:00:00